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ABSTRACT 
 
White-matter damage is a leading cause of neurological handicap. Although hypoxia-
ischemia and excitotoxicity are major pathogenic factors, a role for genetic influences was 
suggested recently. Thus, protracted gestational hypoxia was associated with white-matter 
damage in rat pups but not in mouse pups. Indeed, microglial activation and vessel-wall 
density on postnatal days (P) 1 and P10 were found increased in both mouse and rat pups, but 
cell death, astrogliosis, and myelination were only significantly altered in hypoxic rat pups. 
We investigated whether this species-related difference was ascribable to effects of antenatal 
hypoxia on the expression of glutamate receptor subunits using immunocytochemistry, PCR 
and excitotoxic double hit insult. Quantitative PCR in hypoxic mouse pups on P1 showed 2- 
to 4-fold downregulation of the AMPA-receptor subunits GluR1, 2, and 4; of the kainate-
receptor subunit GluR7; and of the metabotropic receptor subunits mGluR1, 2, 3, 5, and 7. 
None of the glutamate-receptor subunits was downregulated in the hypoxic rat pups. NR2B 
was the only NMDA-receptor subunit that was downregulated in hypoxic mice but not in 
hypoxic rat on P1. Ifenprodil administration to induce functional inhibition of NMDA 
containing NR2B-subunit receptors prevented hypoxia-induced myelination delay in rat pups. 
Intracerebral injection of a glutamate agonist produced a larger decrease in ibotenate-induced 
excitotoxic lesions in hypoxic mouse pups than in normoxic mouse pups. Gestational hypoxia 
may regulate the expression of specific glutamate-receptor subunits in fetal mice but not in 
fetal rats. Therefore, genetic factors may influence the susceptibility of rodents to white-
matter damage. 
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\body INTRODUCTION  
 
 Periventricular white matter damage (PWMD) and subsequent cortical damage are the 
leading causes of cerebral palsy (CP) limited to preterm birth (1, 2). Animal models have been 
developed to unravel the mechanisms underlying these brain lesions. Factors that seem 
involved in the pathophysiology of CP in these models include hypoxia and ischemia, 
infection and inflammation, excitotoxicity, accumulation of reactive oxygen species, and 
deficiencies in growth factors (3, 4). These factors seem to act in combination to cause 
damage to the developing white matter. 
Glutamate accumulation may be a mechanism common to many risk factors for CP. 
Glutamate, the major excitatory neurotransmitter, acts via several groups of receptors, 
namely, N-methyl-D-aspartate (NMDA) receptors, alpha-3-amino-hydroxy-5-methyl-4-
isoxazole (AMPA) receptors, kainate receptors, and metabotropic receptors (mGluRs). 
Excessive activation of glutamate receptors may cause cell vulnerability, in part as a result of 
intracellular calcium influx (5, 6). Intracerebral injection of glutamate agonists into the 
neocortex and white matter of newborn rodents produces histological lesions that mimic the 
brain damage observed in preterm neonates (7-10). 
Several studies suggest that genetic factors may influence the susceptibility of very 
preterm infants to PWMD. The occurrence of CP may depend, at least in part, on 
polymorphisms in genes for tumor necrosis factor-alpha (TNF-α) and mannose-binding lectin 
(11-13). The genetic regulation of glutamate-receptor expression also plays a major role 
throughout development and responds to changes in the cerebral environment (14, 15). 
We recently showed that protracted prenatal hypoxia in rats caused dramatic white-
matter damage in the pups, with microgial activation and oligodendrocyte death leading to 
deficient myelination (16). To investigate a potential role for genetic factors, we compared 
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brain damage in mouse and rat pups subjected to similar levels of antenatal hypoxia. Damage 
was considerably milder in the mouse pups than in the rat pups. Mice and rats descend from a 
common ancestor and share many reproductive, developmental, morphological, and 
anatomical similarities, despite substantial genomic differences. We therefore investigated 
whether the effects of gestational hypoxia on the regulation of glutamate-receptor subunits 
differed between mice and rats. We found that antenatal hypoxia affected the subunit 
composition of glutamate receptors in mice, thereby reducing brain-damage severity. This 
effect was not found in rats. Among NMDA receptor subunits, NR2B was found to play a 
crucial role in the difference between mice and rats regarding susceptibility to hypoxia-
induced white-matter damage. 
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 RESULTS  
 
Gestational hypoxia leads to inflammation without white-matter damage in mouse pups 
but causes white-matter damage in rat pups 
Pups were studied on three time points, synchronizing brain development stages 
between the two species according to the cortical myelin density, the principal endpoint in this 
study (see methods).  
We first investigated whether protracted gestational hypoxia produced similar brain 
abnormalities in mouse and rat pups. No difference in body temperature was found between 
mouse pups subjected to prenatal hypoxia and in controls (data not shown). Hematoxylin-
eosin staining of sections from hypoxic and normoxic mouse pups showed comparable 
findings, with no white-matter lesions. In contrast, white-matter lesions were seen in rat pups 
(data not shown). Vessel-wall density in white matter as assessed using glucose-transporter-1 
(GLUT1) immunostaining was significantly increased in rats (Fig 1A) and mice (Fig 2A, 
supplemental Fig 1A-B) during the first week of life; density was normal on P10 in mice and 
P14 in rats (data not shown). Cingular cortex and basal ganglia from mouse pups exhibited a 
similar transient increase in neonatal angiogenesis, suggesting that gestational hypoxia led to 
fetal hypoxemia, and therefore that absence of fetal hypoxemia was not the reason for absence 
of white-matter damage in mouse pups. Tomato lectin (TL) immunostaining produced similar 
findings with an increased density of activated macrophages in the white matter on both 
hypoxic rat and mouse pups (Fig 1B-2B, supplemental Fig 2C-F). Gestational hypoxia in 
mice was not associated with increased cell death in the cortex or white matter (Fig 2C). 
Conversely, hypoxia in rats was associated with increased cell death in the white matter at the 
early stage (Fig 1C).  
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Glial phenotype following gestational hypoxia differs between mouse and rat pups 
Astrogliosis as assessed using glial fibrillary acidic protein (GFAP) 
immunostaining was significant in cingular white matter from intermediate and late stages 
rat pups subjected to gestational hypoxia (Fig 1D). In contrast, no significant astrogliosis 
was detected in cingular white matter from hypoxic mouse pups at the same stages (Fig 
2D). Similarly, no difference in astrocyte density was noted throughout the cortex and 
basal ganglia obtained from hypoxic mouse pups, compared to controls (data not shown). 
White matter myelination evaluated at the intermediate and late stages using MBP 
immunohistochemistry was normal in hypoxic mouse pups (Fig 3A-E) but altered in 
hypoxic rat pups (Fig 3F-J). We failed to demonstrate any difference between male and 
female both in myelination defect observed in rat pups subjected to prenatal hypoxia. 
Similar findings were obtained by quantitative real-time PCR for MBP transcripts 
(supplemental Fig 2A-B). These finding were observed in cingular white matter, external 
capsule or lateral corpus callosum. Figure 4 compared the panel of cellular markers 
assessed between rat and mouse pups normalized to respective controls. We found a 
statistically significant difference in astrogliosis and myelination defect between the two 
species. 
 Taken together, these results show different phenotypes in mouse and rat pups 
exposed to hypoxia during gestation. 
 
Expression of specific glutamate-receptor subtypes is downregulated in mouse pups 
exposed to gestational prenatal hypoxia 
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Because excitotoxicity and genetic regulation of glutamate-receptor expression are 
known to play a key role in brain damage (8, 14, 17, 18), we investigated whether glutamate-
receptor expression was altered by hypoxia, and whether these alterations differed between 
rats and mice, potentially explaining the phenotypic differences noted between these two 
species. We assessed the expression of glutamate-receptor subtypes in rat and mouse at early, 
intermediate and late stages of brain development. Quantitative real-time PCR in hypoxic 
mice at the early stage demonstrated a significant 2- to 4-fold downregulation of the AMPA-
receptor subunits GluR1-2-4, the kainate receptor subunit GluR7, and the metabotropic 
receptor subunits mGluR1, 2, 3, 5, 7 in at least 6 animals in two separate experiments, 
compared to normoxic controls (Table 1). Testing at later time points showed that the main 
differences were largest during the first few days after birth and resolved by the intermediate 
stage. Only metabotropic receptor subunit mGluR1 was downregulated at the early and the 
late stage and kainate receptor KA2 at the late stage (Table 1). In contrast, gestational 
hypoxia in mice induced no changes in the expression of the AMPA/kainate subunits GluR3, 
5 and 6 or in the metabotropic receptor subunits mGluR4 and 6 (Table 1). In hypoxic rats, at 
all stages, none of the AMPA, kainate, or metabotropic receptor subunits showed differences 
in expression levels compared to control rats (data not shown).  
Among the NMDA receptor subtypes, NR2B was the only downregulated subunit at the 
early stage in mice (Table 1 and Fig 4A). The NR2C subunit was downregulated only at the 
later stage (Table 1). In rats, none of the NMDA receptor subunits was downregulated (data 
not shown), even NR2B at the early stage (Fig 4B), when most of the white-matter damage 
occurred. No difference was observed between male and female pups. We also performed 
analysis of each NMDA receptors subunits, at the three developmental stages and in three 
areas of the developing brain, including motor (M), somatosensori (SS) and visual cortex (V). 
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These data did not shown any difference in rat pups subjected to antenatal hypoxia compared 
to the controls (supplemental Fig 3). 
Western blotting for NR2B protein at the early stage also confirmed downregulation at 
plasmatic membranes in hypoxic mouse pups (Fig 4C). Performing similar analysis for NR2B 
and NR1 subunits failed to demonstrate any downregulation in hypoxic rat pups at any 
developmental stage (Fig 4C and supplemental Fig 4). 
To obtain further evidence that changes in glutamate-receptor expression were involved in 
the ability of mouse pups to withstand gestational hypoxia, we measured NMDA-receptor 
density using binding of tritiated dizocilpine (
3
H-MK-801) in membrane-enriched cortex 
preparation from mouse pups at the early and intermediate stage. No difference was found 
between the two groups at either age in two separate experiments (Fig 4D). This result 
suggests that the role for antenatal hypoxia in modulating white-matter damage may involve 
qualitative rather than quantitative regulation of the ability of glutamate to bind to NMDA 
sites.  
 
Functional inhibition of NR2B receptors prevented delayed myelination induced by 
hypoxia in rat pups 
Because NR2B was the only NMDA-receptor subunit that showed early 
downregulation in response to gestational hypoxia in mice, we investigated the potential role 
for NR2B in the myelination defect seen in rat pups subjected to prenatal hypoxia. Rats were 
given intraperitoneal ifenprodil hemitartrate (2.5 mg/kg; Tocris, Bristol, UK), from E19 to P3, 
to inhibit heteromeric NMDA receptors containing NR2B subunits. Ifenprodil fully reversed 
the myelination defect in hypoxic rats, which exhibited similar white-matter myelination to 
that seen in mice (Fig 5A-D), in both the lateral corpus callosum and the cingular white 
matter.   
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Gestational hypoxia prevented excitotoxic-induced lesions in mouse pups 
We investigated the impact of NR2B-subunit downregulation on the response of the 
developing brain to an excitotoxic challenge. Ibotenate, a glutamate agonist that binds to 
NMDA and metabotropic subtypes, was injected intracerebrally to mouse and rat pups on P2. 
The size of the resulting excitotoxic lesion in the white matter and cortical plate was measured 
on P6. In both the white matter and the cortex, the size of ibotenate-induced lesions was 
significantly reduced in hypoxic mouse pups (either male or female) compared to normoxic 
mouse pups (Fig 6A). In contrast, no significant reduction in lesion size was noted in the 
hypoxic rat pups (Fig 6B). At a later time point (P21) we found that this preconditioning 
effect has been lost in mice (Supplemental Fig 5A). Comparison (normalized to controls) of 
ibotenate-induced lesion size in cortex and white matter between hypoxic rat and mouse pups 
was shown in Fig 7. This preconditioning effect of antenatal hypoxia was not observed in 
hypoxic rat pups but was again observed in both cortex and white matter when rat pups were 
injected with ifenprodil. This result suggests that NR2B dowregulation (in hypoxic mice) or 
inhibition in (treated rats) was, at least in part, responsible for the species-dependent effect of 
antenatal hypoxia on excitotoxic-induced brain lesion. 
NMDA intracerebral injection in mouse demonstrated a non significant reduction in 
lesion size of both cortical and white matter damage (Supplemental Fig 5B). These data 
suggest that antenatal hypoxia-induced changes in metabotropic receptors expression, shown 
in Table 1 should play an additional role in the preconditioning effect of antenatal hypoxia. 
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DISCUSSION 
 
In this study, we investigated the mechanism by which protracted gestational hypoxia 
results in milder brain damage in mice than in rats. Gestational hypoxia was associated with 
increased angiogenesis and an inflammatory response in mouse pups during the first postnatal 
week. Surprisingly, mouse pups exhibited no increase in cell death leading to histological 
lesions, no astrogliosis, and no myelination defect, all of which were found in rat pups. This 
difference between these two species suggests that specific animal models may be relevant to 
delineate discrete mechanisms involved in PWMD. Mice and rats have significant genomic 
differences between each other and with humans, and it has been shown that genetic factors 
may influence the susceptibility to PWMD and subsequent CP in very preterm infants (11, 12, 
17). Specific genetic polymorphisms for endothelial nitric oxide synthase (eNOS) or 
plasminogen activator inhibitor-2 in human infants may contribute to spontaneous preterm 
birth followed by a diagnosis of CP. Cerebral palsy was associated with the beta-2 adrenergic 
receptor gln27glu in white non-Hispanic children and with the plasminogen activator 
inhibitor-1 in Hispanic children (17, 18). Similarly, common genetic variants in genes 
encoding pro- or anti-inflammatory cytokines may influence the risk for spontaneous preterm 
birth. To our knowledge, no evidence has been reported that the genetic background may 
influence animal models of white-matter damage. Results reported by the Rat Genome 
Sequencing Consortium in 2004 suggest that several aspects of genome evolution might be 
accelerated in rats compared to mice. Rats have a number of genes that are not found in mice, 
including genes involved in immunity, the production of pheromones, the breakdown of 
proteins, and the detection and detoxification of chemicals. Also, about 50 chromosomal 
rearrangements occurred in each of the rodent lines after divergence from their common 
ancestor. However, about 90% of rat genes have counterparts in the mouse and human 
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genomes; and the rat, mouse, and human genomes encode similar numbers of genes (19-23). 
We therefore suggest that differences in genetic background between mice and rats may be 
one possible explanation for the neuroprotective effect of hypoxia in mice but not in rats.  
Here, we show that one explanation for the decreased susceptibility to hypoxia-induced 
white-matter damage in mice, compared to rats, may consist in downregulation of specific 
glutamate-receptor subunits, able to decrease the vulnerability to excitotoxic insults. Several 
lines of evidence point to a role for neuronal glutamate receptors in many neurological 
disorders in neonates and adults (5, 8, 24-27). Here, we documented downregulation just after 
birth of the AMPA-receptor subunits 1, 2, and 4; of the kainate-receptor subunit 7; and of the 
metabotropic receptor subunits 1, 2, 3, 5, and 7 in hypoxic mouse pups but not in hypoxic rat 
pups. Among NMDA-receptor subunits, NR2B was markedly downregulated on P1 in mice, 
and the subsequent changes in glutamate-receptor expression were consistent with previous 
data (28). Such transient change may severely impact cortex and white matter development in 
the brain challenged by adverse events occurring during perinatal period (1, 16). Over the last 
few years, an increasing number of studies have established that NR2B is involved in a 
variety of synaptic signaling events and protein-protein interactions. Activation of NR2B-
subtype NMDA receptors triggers a variety of disorders such as schizophrenia, Parkinson’s 
disease, Alzheimer’s disease, and Huntington’s disease (29). NR2B is expressed during 
processes involving oligodendrocytes, and NMDA receptors are extremely sensitive to 
ischemia (25). Moreover, activation of NR2B-containing NMDA receptors results in 
excitotoxicity, whereas activation of NR2A-containing NMDA receptors promotes neuronal 
survival (15). In accordance with these findings, NR2B was the only NMDA subunit that 
showed early significant downregulation in our mouse pups subjected to gestational hypoxia. 
Moreover, ifenprodil, an inhibitor of heteromeric NR2B-containing NMDA receptors, 
completely reversed the myelination deficiency in hypoxic rat pups, suggesting that NR2B 
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may play a key role in hypoxia-induced white matter damage. The promoters of genes that 
encode the NR1, NR2B, NR2C, GluR1, GluR2, and KA2 subunits share several 
characteristics, including multiple transcriptional start sites and neuron-selective expression. 
In most cases, the promoter regions include elements that guide expression in neurons (14). 
The 5’ promoter region of mouse NR2B has been cloned by two independent groups (30, 31). 
Here, genomic DNA from mouse and rat-tail samples was amplified, and NR2B promoter in 
each species was sequenced to identify regulatory elements and factors that may control 
NR2B expression in the brain (supplemental Fig 1). Direct sequencing identified a difference 
in a neuron cis-acting element between rats (CCAGGAG) and mice (CGAGAGA) 
(supplemental Fig 1, box 1). This element may play a role in combination with other cis-
acting elements to confer neuron-specific gene expression (30, 32). Therefore, we suggest that 
the mutation in this motif in rat NR2B promoter may contribute to explain the transcriptional 
difference between rats and mice after gestational hypoxia. Conversely, no difference was 
detected between the two species in a sequence known as the neuron-restrictive silencer 
element (RE1 or NRSE; supplemental Fig 1, box 2), which represses transcription by 
associating with a repressor protein called REST or NRSF. This suggests that a potential 
regulatory phenomenon in NR2B promoter may be independent from REST in our model of 
gestational hypoxia. 
Finally, we demonstrated that prenatal hypoxia was neuroprotective against cortical 
and white-matter lesions induced by intracerebral ibotenate injection on P2 in mouse pups but 
not in rat pups. In various animal models, a short period of hypoxia (preconditioning) may 
prevent ischemia- or stroke-related brain injury (33-35). In this study, we report that even 
prolonged hypoxia was neuroprotective in mice during a critical developmental window. To 
our knowledge, we provide the first evidence prenatal hypoxic preconditioning induces 
 13 
downregulation of specific glutamate-receptor subunits, leading to a neuroprotective effect 
also detectable after pharmacological inhibition of NR2B subunit.  
In conclusion, this study documented a previously undescribed biological effect of 
gestational hypoxia on glutamate-receptor regulation in mice. It establishes that genetic 
factors affect the susceptibility of the developing white matter to injury, in addition to other 
recognized risk factors. Further studies are needed to identify glutamate-receptor promoter 
fragments that may be candidates for designing gene-targeting constructs to deliver transgenes 
and other therapeutic agents to the developing brain.  
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MATERIALS AND METHODS 
 
Animal models  
All experimental protocols and animal housing procedures complied with INSERM 
guidelines and with the Policies on the Use of Animals and Humans in Neuroscience 
Research (revised and approved by the Society for Neuroscience in January 1995).  
Gestational hypoxia 
Pregnant Sprague-Dawley rats and Swiss, Balb/c/j, DBA/2 or CBA mice (Janvier, Le 
Genest-St-Isle, France) were placed in normoxic or hypoxic (10% O2-90% N2) gas chambers 
(Biospherix, Redfield, NY) and monitored as previously described (16). Hypoxia exposure 
lasted from embryonic day (E) 5 to E19 in rats and from E5 to E18 in mice. After delivery, 
normoxic (control) and hypoxic pups were studied on three time points, considered to better 
synchronize brain development stages between the two species, according to the cortical 
myelin density: P1 (early), P7 (intermediate), and P14 (late) for rat pups and P1 (early), P10 
(intermediate), and P21 (late) for mouse pups. 
Excitotoxic brain lesions 
Ibotenate (Tocris, Bristol, UK) is a glutamate analogue that activates both NMDA and 
metabotropic receptors; it does not activate AMPA or kainate receptors. Ibotenate (5 µg) or 
NMDA (2µg) was injected intracerebrally on P2 or P21 to mouse and rat pups, as previously 
described (7, 8, 36-38). At least 12 animals of each treatment group were killed by 
decapitation 4 days after the injection (i.e., on P6 or P25), and the brains were processed as 
previously described to ensure accurate and reproducible determination of the maximal sagittal 
fronto-occipital diameter of the lesion, which served as an index of lesion volume (37). In all the 
experiments described below, two investigators blinded to treatment group determined the 
size of the lesion in each pup. 
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Immunohistochemistry 
For the detection of myelin basic protein (MBP) detection, brains from rats pups killed 
at the intermediate or the late stage after gestational exposure to normoxia or hypoxia were 
fixed in 4% formaldehyde for 5 days. After embedding in paraffin, 10-µm sections were cut 
coronally from the frontal to the occipital pole. Sections were incubated with primary 
antibody diluted 1:1000 (Sigma Biosciences, St Louis, MO). Labeled antigens were detected 
using the streptavidin-biotin peroxidase complex (Amersham, Buckinghamshire, UK) 
containing the chromogen diaminobenzidine.  
Normoxic or hypoxic mouse and rat pups were perfused transcardially with 4% 
paraformaldehyde in phosphate buffer (0.12 M, pH 7.4) under inhaled isoflurane anesthesia 
(Abbott France, Rungis, France). The brains were post-fixed, cryoprotected in sucrose, frozen 
and cut into coronal sections 10 µm in thickness. The sections were incubated overnight with 
primary antibodies (supplemental Table 1). The primary antibodies were visualized using 
streptavidin-biotin-peroxidase complex as described above. At least 6 animals were included 
in each experimental group. Experiments were repeated three times. Adjacent sections were 
used as negative controls in which incubation with the primary antibody was omitted. Two 
investigators blinded to treatment group independently estimated the number of positive cells 
seen in cross-sections in an area measuring 0.0625 mm
2 
(x40 magnification) or 1 mm
2 
(x10 
magnification). 
 
Quantification of myelination  
The optical density (OD) of MBP-immunoreactive fibers was measured in the 
cingulum of coronal sections from mice and rats at the later stage (+2.16 to -0.36 mm from 
the bregma). OD was measured at x100 magnification using image-analysis software (ImageJ, 
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NIH, MA, http://rsb.info.nih.gov/ij/) that read OD as gray levels, calculated the area and pixel 
value statistics of user-defined selections, and generated density histograms. Nonspecific 
background densities were measured in a region devoid of MBP immunostaining at each brain 
level and were subtracted from the cingulum values. OD was analyzed in at least 10 animals 
per group (normoxic or hypoxic) from three separate experiments and in at least 4 sections per 
brain.  
 
Quantitative real-time PCR 
DNA-free total RNA from normoxic and hypoxic brain cortex including white matter 
or from motor (M), somatosensory (SS) or visual (V) cortices  was obtained using a protocol 
adapted from Chomczynski and Sacchi (39). Primers for real-time RT-PCR were designed 
using M-fold and Oligo6 software, based on published cDNA sequences encoding mouse and 
rat glutamate receptors and the myelination marker MBP. The nature of the amplified DNA 
was confirmed by sequencing. To standardize gene expression across samples, we first 
compared the expression levels of four well-known housekeeping genes (glyceraldehyde-3-
phosphate dehydrogenase [GAPDH], 2-microglobulin, hypoxanthine-guanine 
phosphoribosyltransferase [HPRT], and -glucoronidase) within the samples. For reverse 
transcription, we used 600 ng of total RNA and the Iscript cDNA synthesis kit (Bio-Rad, 
Hercules, CA).  Real-time PCR was set up using sybergreen-containing supermix (Bio-Rad) 
for 50 cycles with a three-step program (25 sec denaturation at 96°C, 30 sec annealing at 
60°C, and 30 sec extension at 72°C). Amplification specificity was assessed by melting curve 
analyses. Each experiment was run twice with a least 6 animals per group, and in both cases, 
samples were assessed in triplicate. 
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Binding 
NMDA receptor density was evaluated based on the binding of tritiated dizocilpine 
(
3
H-MK-801; Perkin Elmer, Zaventen, Belgium) in membrane-enriched cortex preparation 
(40). Briefly, 
3
H-MK-801 (2.5-17 nM ) was incubated for 2 hours at room temperature with 
150-200 µg of proteins in 0.5 ml of Hepes (10 mM, pH 7.4) buffer containing L-glutamate 
(100 µM) and glycine (30 µM). Nonspecific binding was evaluated by adding 30 µM of 
unlabeled MK-801 (ICN Biomedicals Inc., Costa Mesa, CA). Incubations were stopped by 
rapid filtration through glass-fiber filters (GF/B; Whatman, Sigma, Saint Quentin Fallavier, 
France). Binding capacity and Kd were estimated by Scatchard analysis in two separate 
experiments.  
 
Western Blot 
Membrane proteins were extracted from forebrain cortex, including white matter, 
taken from mouse and rat pups. Extraction was achieved by homogenization in Hepes buffer 
containing protease inhibitors from Sigma, according to the manufacturer’s instructions. We 
loaded 50 µg of protein from each sample and membranes were incubated overnight with a 
specific polyclonal antibody against NR2B or NR1 (Alomone Labs, Jerusalem, Israel) diluted 
1:200 or with an anti- -actin goat antibody (Santa Cruz Biotechnology) diluted 1:10,000. 
Western blot experiments were run in triplicate.  
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Statistical analysis 
The data were analyzed using Student’s t-test or one-way analysis of variance 
(ANOVA). When a main effect was significant by ANOVA, post hoc multiple-comparison 
tests were performed (Bonferroni, Dunnett, or Kruskal-Wallis; Graph-Pad Prism version 4.01 
for Windows, Graph-Pad Software, San Diego, CA). 
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FIGURE LEGENDS 
 
Figure 1: Gestational hypoxia induces histological brain damage in rats 
A: Quantification of glucose transporter protein-1 (GLUT1)-immunoreactive vessel walls in 
white matter (WM) of control (ctl) and hypoxic (hx) rat pups at the early stage. ***P<0.001. 
B: Quantification of Tomato-lectin (TL)-immunoreactive microglial cells in WM of control 
and hypoxic rat pups at the early and intermediate stages. ***P<0.001. 
C: Quantification of TUNEL-reactive dying cells in the cortex and WM of control and 
hypoxic rat pups at the early and intermediate stages. ***P<0.001. 
D: Quantification of glial fibrillary acidic protein (GFAP)-immunoreactive astrocytes in the 
cingular WM of control and hypoxic rat pups at the intermediate and late stages. *P<0.05 and 
***P<0.001. 
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Figure 2: Gestational hypoxia induces milder histological brain damage in mice than in 
rats 
A: Quantification of glucose transporter protein-1 (GLUT1)-immunoreactive vessel walls in 
the white matter (WM) of control (ctl) and hypoxic (hx) mouse pups at the early stage. 
**P<0.01. 
B: Quantification of Tomato-lectin (TL)-immunoreactive microglial cells in the WM of 
control and hypoxic mouse pups at the early and intermediate stages. * P<0.05 and *** 
P<0.001. 
C: Quantification of cleaved caspase-3-immunoreactive dying cells in the cortex and WM of 
control and hypoxic mouse pups at the early and intermediate stages. 
D: Quantification of glial fibrillary acidic protein (GFAP)-immunoreactive astrocytes in the 
cingular WM of control and hypoxic mouse pups at the intermediate and late stages.  
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Figure 3: Gestational hypoxia induces a myelination defect in rats but not in mice 
A: Optical density (OD) quantification of MBP staining in the lateral corpus callosum from 
control and hypoxic mouse pups at the intermediate and late stages. 
B, C: Microphotographs showing MBP-immunoreactive oligodendrocytes on coronal sections 
from control (C) and hypoxic (D) mouse pups at the late stage. The boxes delineate the 
regions where OD was measured. 
D, E: Microphotographs at higher magnification showing MBP-immunoreactive 
oligodendrocytes on coronal sections from control (E) and hypoxic (F) mouse pups at the late 
stage.  
F: OD quantification of MBP-staining in the lateral corpus callosum from control and 
hypoxic rat pups at the intermediate and late stages. ** P<0.01 
G, H: Microphotographs showing MBP-immunoreactive oligodendrocytes on coronal 
sections from control (I) and hypoxic (J) rat pups at the late stage. The boxes delineate the 
regions where OD was measured. 
I, J: Microphotographs at higher magnification showing MBP-immunoreactive 
oligodendrocytes on coronal sections from control (K) and hypoxic (L) rat pups at the late 
stage. 
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Figure 4: Comparison of cellular markers between mouse and rat brains compared to 
respective controls 
Quantification of GLUT1-immunoreactive vessel walls, TL-immunoreactive microglial cells, 
GFAP-immunoreactive astrocytes and MBP optical density in the WM of hypoxic rat pups at 
different stages, normalized to normoxic controls. Statistical analyses show significant 
differences in astrogliosis and myelination defects between the two species. * P<0.05 and *** 
P<0.001. 
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Table 1: NMDA, AMPA/kainate and metabotropic receptors subunits were significantly 
downregulated after gestational hypoxia in mouse pups. P<0.05, ** P<0.01, and *** 
P<0.001 
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Figure 5: NR2B subunit ontogenic neocortical pattern of mRNAs, Western blot analysis 
of NR2B protein expression and 
3
H-MK-801 binding in control and hypoxic mouse and 
rat pups. 
A, B: Expression of NR2B subunits mRNAs in control and hypoxic mouse (A) and rat (B) 
pups cortex including white matter at the three stages. ** P<0.01 
C: NR2B protein expression in control and hypoxic mouse and rat pups at the early stage. 
NR2B protein expression was downregulated in hypoxic mouse pups but not in hypoxic rat 
pups. 
D: H-MK-801 binding in control and hypoxic mouse pups at the early and intermediate 
stages. 
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Figure 6: Ifenprodil administration reverses the myelination defect in rats at the late 
stage 
A: Optical density quantification of myelin basic protein (MBP) staining in the lateral corpus 
callosum from late stage control and hypoxic rat pups treated with ifenprodil (ifen). *P<0.05 
B, D: Microphotographs showing MBP-immunoreactive oligodendrocytes on coronal sections 
of control rats pups (B), hypoxic rat pups (C), and ifenprodil-treated hypoxic (D) rat pups at 
the late stage. 
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Figure 7: Hypoxia protects newborn mice, but not newborn rats, from excitotoxic-
induced brain lesion 
Gestational hypoxia reduced lesion size both in the cortex and WM in mice given 
intracerebral ibotenate (Ibo). Gestational hypoxia did not reduce lesion size in rats given 
intracerebral ibotenate but added to intraperitoneal injections of ifenprodil (ifen), gestational 
hypoxia reduces ibotenate-induced cortical lesion in neonatal rats.  
* P<0.05,  ** P<0.01 and *** P<0.001 compared to normoxic controls; § P< 0.05.   
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SUPPLEMENTAL FIGURE LEGENDS 
 
Table 1: Primary antibodies used in the study 
GLUT1: Glucose Transporter 1 
GFAP: Glial Fibrillary Acidic Protein. 
MBP: Myelin Basic Protein 
 
Figure 1: Histological brain phenotype induced by protracted gestational hypoxia in 
mice  
A-B : Microphotographs showing GLUT1 immunoreactive vessel walls in cingulum of 
control (A) and hypoxic (B) mouse pups at the early stage. 
 C-F: Tomato-lectin immunoreactive microglial cells in mouse control (C-E) and hypoxic (D-
F) pups at the early (C-D) and intermediate stages (E-F). 
 
Figure 2: Gestational hypoxia induces a decreased myelination transcription in rats but 
not in mice  
A: Myelin basic protein (MBP) mRNA expression in control and hypoxic mouse pups at the 
late stage. 
B: MBP mRNA expression in control and hypoxic rat pups at the late stage. ** P<0.01 
 
Figure 3: Ontogenic pattern of rat NMDA receptors subunits mRNA in the motor, 
somatosensory and visual cortex at different stages 
A-C: NMDA receptor subunits expression in control and hypoxic rat pups motor (M), 
somatosensory (SS) and visual (V) cortex at the early (A), intermediate (B) and late (C) 
stages.  
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Figure 4: NR2B and NR1 protein expression in control and hypoxic mouse rat pups at 
different developmental stages.  
Neither NR1 nor NR2B protein expression was found altered by gestational hypoxia at early 
and intermediate stages. NR2B but not NR1 appeared to be upregulated in hypoxic rat pups at 
the late stage. 
 
Figure 5: Gestational hypoxia impact on excitotoxic-induced brain damage in mice. 
A: Gestational hypoxia did not reduce lesion size in the cortex of mice given intracerebral 
ibotenate (Ibo) at the late stage (P21). At this developmental stage, no white matter lesion 
was detectable. 
B: Gestational hypoxia induced a non significant reduction in cortical and white matter lesion 
size of neonatal mice given intracerebral NMDA. 
 
Figure 6: Sequence of NR2B promoter from rats and mice 
Direct sequencing of genomic DNA from rats and mice showed a difference in the neuron 
cis-acting element (red box1) but not in the RE1/NRSE motif (red box2). Black boxes show 
the conserved sequences and gray boxes the mutations causing differences between the two 
species. 
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